Abstract: Systems and methods presented herein provide for multivariable model predictive control of a multistep plant. In one embodiment, a model predictive controller (MPC) includes a model of the multistep plant. The MPC is operable to linearize at least two steps of the multistep plant into cycle steps based on the model, to process an output signal from the multistep plant, and to independently control the cycle steps based on the output signal to optimize an output of the multistep plant.

Abstract: Systems and methods presented herein provide for multivariable model predictive control of a multistep plant. In one embodiment, a model predictive controller (MPC) includes a model of the multistep plant. The MPC is operable to linearize at least two steps of the multistep plant into cycle steps based on the model, to process an output signal from the multistep plant, and to independently control the cycle steps based on the output signal to optimize an output of the multistep plant.

Abstract: The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.

Abstract: A oxygen concentrating system comprising an adsorption column having a first end and a second end, a shell enclosing the column and defining a product gas storage space between the column and the shell, a product conduit connecting the product gas storage space to a product output point, a first conduit comprising at least one first valve having at least a first and second configuration, in the first configuration, compressed air flows from the feed point to the first end, and, in the second configuration, waste gas flows from the first end to the waste point, and a second conduit comprising at least one second valve having at least a first and second configuration, in the first configuration, the product gas flows from the product gas storage space to the second end, and, in the second configuration, the product gas flows from the second end to the storage space.

Abstract: A oxygen concentrating system comprising an adsorption column having a first end and a second end, a shell enclosing the column and defining a product gas storage space between the column and the shell, a product conduit connecting the product gas storage space to a product output point, a first conduit comprising at least one first valve having at least a first and second configuration, in the first configuration, compressed air flows from the feed point to the first end, and, in the second configuration, waste gas flows from the first end to the waste point, and a second conduit comprising at least one second valve having at least a first and second configuration, in the first configuration, the product gas flows from the product gas storage space to the second end, and, in the second configuration, the product gas flows from the second end to the storage space.

Abstract: The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease.

Abstract: An electronic voice recognition system utilizes a microphone having noise-cancelling characteristics and a standardizer network to achieve further noise reduction and signal standardization over a range of input levels. The output of the standardizer is coupled to voice processor circuitry which provides a computer-compatable output corresponding to the voice information received. The system may be embodied in a multi-station environment in which the voice reception stations are coupled to a remote central processing location. A variety of processing techniques, including analog and digital, parallel and sequential, may be utilized to pass the voice signals to the processors. Upon successful processing, a confirmation signal is passed to the appropriate voice-originating station.